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Abstract 
Photoluminescent cyclometalated iridium(III) complexes are now a well established 
class of organometallic compounds with advantageous potential applications in biology and 
life science. While these complexes, along with other luminescent transition metals and 
lanthanoid complexes, were initially proposed as alternative markers to organic 
fluorophores in the staining of cells, it is now apparent that their specific biological 
behaviour can make this class of compounds useful in a broader areas of life science such as 
imaging, sensing and therapy. The critical factors for the effective design of cyclometalated 
iridium(III) complexes with specific biological properties are still rather difficult to rationalize 
and often mainly rely of aspects such as the intrinsic charge of the complex, its lipophilicity 
and it aqueous solubility. This review overviews the area of cyclometalated iridium(III) 
complexes in biology, with an emphasis on comparing the various conditions that these 
compounds have been assessed for their biological potential, such as the specific tested 
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cells lines, concentration of internalization, incubation time, and mechanism of cellular 
entrance.  
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1. Introduction 
Cellular imaging has become a very powerful tool in life science [1–4].  The technique 
allows the direct visualization of cells at subcellular resolution, and therefore it can be 
conveniently exploited to image the cell as a whole, specific subcompartments and 
organelles (such as nucleous, mitochondria, and lysosomes, for example), and even the 
presence and concentration of key biological and metabolic species [5–11].  
While label-free techniques that exploits the autofluorescence of endogenous 
molecular species have been extensively developed [12–17], optical imaging commonly 
relies on the incubation of luminescent markers (often referred to as molecular probes or 
cellular imaging agents). The area of organic fluorophores for cellular imaging is certainly 
well advanced and in continuous evolution, and many probes that are now of fundamental 
importance for optical imaging have been developed for various applications within a 
cellular environment [18–23]. While these markers are certainly well established and 
essential in the field, for specific imaging conditions they might be associated with 
drawbacks that are intimately linked to the organic nature of these compounds.  
Typically, luminescent organic molecules have rather small Stokes shifts, often 
resulting in a significant overlap between the absorption and emission spectral profiles 
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[24,25]. Therefore, as the probe accumulates within a specific cellular compartment and its 
local concentration effectively increases, its brightness (defined as the product of molar 
absorptivity and photoluminescent quantum yield) can be reduced due to concentration 
quenching phenomena. As mentioned above, cells are inherently fluorescent due to the 
presence of photoactive endogenous compounds such as flavins, nicotinamides, and indole 
side group of tryptophan amino acids, for example [26–31]. If the excitation and emission 
profiles of the marker in use are in the same region of those of autofluorescent endogenous 
species, it might be difficult to discriminate between the two signals. Lastly, but potentially 
one of the most limiting drawbacks, is represented by the tendency of some organic 
molecules to undergo photobleaching [32–34]. This process occurs once the compound is 
excited to higher energy states, from which unwanted reactivity can occur destroying the 
emissive properties of the marker. It should be noted that some molecular probes can 
undergo extensive photobleaching within very short amount of time (less than one minute), 
limiting the usefulness of the probe for longer-time experiments in live cells. 
In case one of more of the previously listed drawbacks are encountered, depending 
on the specific conditions used for the imaging experiments, it is essential to have 
alternative markers to overcome them. To fulfil this goal, luminescent transition metal 
complexes of low spin d6 electronic configuration such a ruthenium(II), rhenium(I), and 
iridium(III), of d8 electronic configuration such as gold(I) and platinum(II) [10,35–37], as well 
as lanthanoid complexes of visible emitters, such as Eu(III) and Tb(III), or NIR emitters, such 
as Yb(III) [38–42], have been investigated. All these complexes display favourable chemical 
characteristics and advantageous photophysical properties that make them ideal candidates 
for the development of complementary probes to organic fluorophores for applications in 
cellular imaging [43].  
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The transition metal complexes listed above are triplet state emitters, which makes 
them phosphorescent given that their ground state is of singlet spin multiplicity [44,45]. The 
energy stabilization on passing through a singlet to a triplet excited state, promoted by the 
strong spin-orbit coupling of the metal center, ensures that the Stokes shift is much larger 
when compared to fluorescent molecules. This larger shift results in a lack of overlap 
between the absorption and emission profiles, therefore limiting the extent of 
concentration quenching. The lanthanoid complexes also have quite large Stokes shift 
[46,47], derived from the fact that their efficient excitation is obtained via the antenna 
effect, where the coordinated chromophoric ligand is photoexcited to its singlet manifold, 
undergoes intersystem crossing, and eventually transfers the energy to the respective 
emissive states of the lanthanoid cation [48,49]. 
As radiative decay of transition metal complexes is forbidden by the spin selection 
rule, given the fact that there is a change in spin multiplicity on decaying from a triplet 
excited state to a singlet ground state, the characteristic excited state lifetime of these 
species is typically longer compared to organic fluorophores [50,51]. Transition metal 
complexes usually decay within a time range between hundreds of nanoseconds up to 
microseconds, whereas spin-allowed fluorescence from organic species typically occurs 
within few nanoseconds. Also in the case of lanthanoid complexes [47], f-f 
interconfigurational electronic transitions are parity and often spin forbidden, resulting in 
elongated excited state lifetimes ranging between microseconds and milliseconds. A long 
excited state lifetime can be exploited to significantly reduce unwanted background 
autofluorescence using time-gated detection associated with microscopy techniques 
[52,53]. In fact, a time delay of few hundreds of nanoseconds would ensure that the 
luminescence signal coming from the cells is exclusively belonging to the metal centre 
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probe, because autofluorescent processes are already fully completed. This aspect is 
especially useful when the excitation and emission profiles of the probe overlap with those 
of endogenous fluorescent species. 
Depending on the specific chemical nature of the coordinated ligands, metal 
complexes of ruthenium(II), rhenium(I), iridium(III), gold(I) and platinum(II) can be quite 
kinetically inert, which favours lack of reactivity through ligand exchange that can 
potentially lead to cytotoxicity. On the other hand, the typical lability of lanthanoid cations 
is usually overcome by coordination with high denticity ligands, making the resulting 
complexes stabilized via the chelate effect. These design factors can also indeed aid in 
reducing photobleaching, thus making metal complexes viable molecular probes for longer 
timescale imaging with live cells without significant loss of photoluminescence 
[37,39,51,54].  
While they certainly possess advantageous photophysical properties, especially in 
the case of phosphorescent transition metals, it is essential to consider their ability to 
sensitize singlet oxygen [55–57]. Production of singlet oxygen within live cells can lead to 
extensive photocytotoxicity, even in cases when the metal complex is non cytotoxic when 
incubated within live cells that are kept in the dark without photoexcitation. In fact, this 
very characteristic has sparked the investigation of many metal complexes from cellular 
markers to phototherapeutic agents in the field of photodynamic therapy (PDT) [58–62].  
Amongst the various metal complexes, cyclometalated iridium(III) species [63–69] 
have received extensive investigation for applications in life science. Typically, these 
complexes comprise an iridium(III) centre bound to two cyclometalated ligands such as 
phenylpyridine, and one bidentate ligand such as a diimine (although it is not uncommon to 
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find two monodentate ligands). The chemical nature of this family of complexes can be 
readily tuned by chemical variations of the coordinated ligands, this allowing tuning of 
properties such as charge, lipophilicity, and solubility, as well as photoluminescent 
characteristics. In fact, it is known that iridium complexes can be tuned to be emissive 
across the entire range of the visible spectrum, from blue to red, and further in the near-
infrared region. Given this high versatility, it is not surprising that a large number of iridium 
complexes have been investigated for their potential application as cellular markers and 
therapeutic agents.  
The strategies adopted to design iridium(III) complexes for life science can be 
broadly divided into two categories. Complexes can be bioconjugated to biological or 
targeting vectors, with the aim of inducing a specific biological behaviour. For example, the 
complex could be bioconjugated to target localization within a specific organelle such as 
mitochondria, to interact with specific biological species such as a proton in the 
measurement of intracellular pH, or to sense and quantify the presence of specific analytes. 
The complexes can also be designed to exhibit a photophysical response that is able to be 
modulated by the targeted even, as for example in the case of fluorogenic turn-ON 
complexes or ratiometric complexes. On the other hand, the complexes might lack 
bioconjugation, and their biological behaviour can be investigated to elucidate a structure-
activity profile. In this case, it becomes immediately apparent how a rationalization between 
structure and activity is quite complex to achieve, despite the fact that it would be 
extremely beneficial for the design of advanced and superior iridium complexes for targeted 
applications in life science. The main critical aspects that are typically invoked in structure-
activity studies are charge, lipophilicity and solubility [70]. These are indeed very useful, but 
in general these considerations seems to be appropriate for small sub-libraries of complexes 
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that have analogous chemical formulations. What constitute also a complication is the fact 
that very often the experimental conditions used by the research groups worldwide are very 
different, with variations occurring on the specific cells lines used, concentration, incubation 
time, imaging time, and imaging protocol. These aspects often lead to results that are not 
just dependent on the chemical nature and characteristics of the metal complex. 
Nonetheless, the field has rapidly broadened in the past decades from being just limited to 
cellular imaging. Perhaps, it would be essential to further refine the field to find a set of 
common protocols to screen the complexes and aid in further rationalization of structure-
activity relationship?  
This review presents a broad overview of the use of iridium complexes in life science, 
not only with a focus on the specific chemical nature examples of investigated 
cyclometalated iridium(III) complexes, but also trying to gather extended information of the 
various experimental conditions that these species have been used, all of which are 
summarized in Table 1, including determination of parameters such as lipophilicity and 
mechanism of cellular internalization when available. In structuring this review, the 
complexes have been grouped according to their specific localization, including cytoplasm, 
nucleous, lysosomes, mitochondria, and endoplasmic reticulum. 
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Table 1. Summary of data and conditions for the cyclometalated iridium(III) complexes presented in this review. 
Organelle Probe Charge Application Cell linesa Lipophilicity Incubation 
timec,d,e 
Concentration Viability 
dark 
Phototoxic 
index 
IC50 Uptake 
mechanism 
(method of 
detection) 
Ref 
C
Y
T
O
P
L
A
S
M
 
1 - 2 Cationic Bioimaging HeLa  
MCF-7 
HCT-8 
- 24 h  100 µM >90% - - - 
(Fluorescent 
intensity) 
[71] 
3 - 6 Cationic Bioimaging HeLa 
MCF-7 
HCT-8  
- 24 h  100 µM >90% - - - 
(Fluorescent 
intensity) 
[63] 
7 Neutral Ratiometric 
probe 
HeLa  
KB 
- 24 h 100 µM >90% - - - 
(Fluorescent 
intensity) 
[72] 
8 Neutral Photoswitcha
ble probe 
KB - 24 h 20 µM >80% - - - 
(Fluorescent 
intensity) 
[73] 
9 Neutral Bioimaging KB - 8 mind 2 mg/mLd - - - - 
(Fluorescent 
intensity) 
[74] 
10a - c 
11a - b 
Neutral 
Cationic 
Bioimaging HeLa  
A549 
1.28 - 1.57 
0.56 - 0.89 
24 h 20 µMf - - 73 - 200 
50 - 120 
Energy-
dependent 
(flow 
[75] 
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cytometry) 
12 Cationic Ratiometric HeLa - 48 h 600 mg/mL >75% - - Endocytosis 
(Fluorescent 
intensity) 
[76] 
13 - 15 Cationic Bioorthogonal 
probes 
CHO-K1  - 1 h 5 µMf - - 50 - 100 - 
(ICP-MS) 
[77] 
 N
U
C
L
E
U
S
/ 
N
U
C
L
E
O
L
U
S
 
16 - 18 
(a - b)  
Cationic Bioimaging HeLa  
MDCK 
(live/fixed) 
0.90 – 3.95 48 h 5 µMf - - 1 - 25 - 
(Fluorescent 
intensity) 
[78] 
19 Cationic Bioimaging HeLa 
KB 
FLS 
-0.12 48 h 100 µM >90% - - Energy-
dependent 
(ICP-AEC) 
[79] 
20a - g Cationic Bioimaging HeLa 
LO2 
-0.09 - 2.12 24 h 20 µM >90% - - Energy-
dependent 
(ICP-AEC) 
[80] 
21 - 23 Cationic Bioimaging HeLa (fixed) 
MCF-7 
(fixed) 
- 24 h 10 – 20 µMf - - 25 – 56 
 
- 
(Fluorescent 
intensity) 
[81,82] 
L
Y
S
O
S
O
M
E
S
 
24 
25 
Neutral 
Cationic 
Bioimaging CHO - 24 h 200 µM - - >200 Energy-
dependent 
(Flow 
cytometry) 
[65] 
26a - i Neutral Bioimaging 4T1 -8.12 - 3.18b 1 h 0.1 µM 39 - 71% - - - 
(Flow 
[83] 
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cytometry) 
27 - 30 Cationic PDT agents A549 
LO2 
1.97 – 2.12 15 min 
(425 nm)e 
20 µMf - 25 - >833 
3 - 23 
- Energy-
dependent 
(Flow 
cytometry) 
[66] 
31 Neutral PDT agent HeLA-S3 - 90 min 
(377 nm)e 
10 µM - 10 - 30%g - Passive 
transport 
(ICP-AEC) 
[84] 
32 Neutral Bioimaging HeLa - 48 h 10 µM >95% - - Energy-
independent 
(Fluorescent 
intensity) 
[85] 
M
IT
O
C
H
O
N
D
R
IA
 
33 Neutral Bioimaging 3T3 
(live/fixed) 
HeLa 
RPE 
- 12 h 10 µM 60% - - Energy-
dependent 
(Fluorescent 
intensity) 
[86] 
34 – 36 
a - d 
Cationic Bioimaging HeLa 
MCF-7 
1.40 – 2.48 48 h 50 µM - -  
1.4 - 3.8  
Endocytosis 
(ICP-MS) 
[87] 
37 - 38 Cationic Bioorthogonal 
probes 
CHO 5.69 – 7.14 6 h 50 µM 76 - 85% - - Passive 
diffusion 
(Fluorescent 
intensity) 
[88] 
39 Neutral PDT agent HeLa-S3 - 10 min 
(465 nm)e 
10 µM - >55%g - Passive 
transport 
(ICP-AEC) 
[89] 
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40 - 43 Cationic Ratiometric 
probe 
A549 - 12 h 10 µM >80% - - - 
(ICP-MS) 
 
[90] 
44a  - c Cationic PDT agents HeLa - 5 min 
(365 nm)e 
5 µM - 3.6 – 9.2 - - 
(ICP-MS) 
[91] 
45a - e Cationic Bioimaging HeLa - 12 h 0.5 µM >85% - - Energy-
dependent 
(ICP-MS) 
[64] 
46 - 48 Cationic PDT agents HeLa 
LO2  
0.77 – 1.42 - 
(405 nm)e 
0.5 µMf - 6.5 - 75 
4.5 - 14 
- Endocytosis 
(ICP-MS) 
[92] 
49a - c Cationic Bioimaging HeLa 0.9 – 1.5 6 h 5 µM - >80%g - Energy-
dependent 
(ICP-MS) 
[93] 
50 - 51 Neutral Bioimaging HOS 
(live/fixed) 
- 24 h 5 µM >80% - - - 
(Fluorescent 
intensity) 
[94] 
52 - 53  Cationic Anticancer 
agents 
HeLa  
A549 
(live/fixed) 
MDB-MA-
231  
PC3 
LO2 
0.23 – 2.12 48 h 10 µMf - - 0.5 - 10 
0.2 - 24 
 
0.3 - 28 
1.0 - >100 
1.5 - 27 
Energy-
dependent 
(ICP-MS) 
[95] 
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54 - 55 Cationic Bioimaging HeLa - 24 h 20 µM >70% - - Energy-
dependent 
(ICP-MS) 
[96] 
56  Cationic Anticancer 
agents 
HeLa 
HepG2 
BEL-7402  
A549 
LO2 
- 48 h 0.5 µMf - - 0.5 
1.1 
1.5 
0.8 
2.6 
Energy-
dependent 
(ICP-MS) 
[97] 
57 - 58 Cationic Bioimaging H9C2 1.86 – 1.87 2 h - 24 h 20 µM >30 - 0% - - Energy-
dependent 
(ICP-MS) 
[98] 
E
N
D
O
P
L
A
S
M
IC
 R
E
T
IC
U
L
U
M
 
59a - c 
60a - c  
Cationic 
Cationic 
Bioimaging HeLa 1.30 – 3.40 48 h 5 µMf - - 1.1 - 6.3 Endocytosis 
(Flow 
cytometry) 
[99] 
61 - 63 Cationic Bioimaging HeLa - 48 h  5 µMf - - 1.0 - 4.2 - 
(Fluorescent 
intensity) 
 
[100] 
64 Cationic Anticancer 
agent 
HeLa 
A549 
MCF-7 
2.12 24 h 10 µMf - - 3.3 
2.0 
3.2 
- 
(Fluorescent 
intensity) 
[101] 
65 Cationic Bioorthogonal 
probe 
CHO-K1 - 20 h  20 µM >80% - - - 
(ICP-MS) 
[102] 
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66 - 67 Cationic PDT agents MCF-7 
SKOV-3 
- 10 sece 2 µM - 5.7 - 5.9 
2.5 - 5.6 
- - 
(Fluorescent 
intensity) 
[103] 
68a - b 
69 - 71a 
71b 
Neutral 
Neutral 
Cationic 
Bioimaging H9c2 2.01 – 2.68 
 
1.68 
24 h 40 µM >85% 
 
0% 
- - Energy-
dependent 
(ICP-MS) 
[98] 
 
a Incubated within live cell lines, unless otherwise stated. 
b Theoretically calculated copying the ChemDraw structures into the structure builder on the web site http://intro.bio.umb.edu/111-112/OLLM/111F98/newclogp.html. 
c Incubation time and concentration are referred to the conditions of the cytotoxicity analysis. 
d Incubation time and concentration are referred to the investigation by confocal luminescence microscopy. 
e Irradiation time; in parenthesis the excitation wavelength is reported. 
f Concentration is referred to the conditions of the internalisation analysis. 
g Only the cytotoxicity upon exposure to light was index. 
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2. Luminescent iridium(III) probes 
2.1 Cytoplasm staining 
The cytoplasm is the diffuse area enclosed between the cellular membrane and the 
nucleous. The cytoplasm hosts organelles and macromolecules, and many metabolic 
processes occur within this space, such glycolysis and protein folding [104]. The transport of 
materials between organelles also occurs in the cytoplasm, due to a process called 
cytoplasmic streaming [105,106]. The various interactions between organelles and 
biomolecules are highly regulated, and therefore imaging of the cytoplasm parameters and 
functions is a key component in life science [104]. 
 
Fig. 1. Examples of iridium complexes with cytoplasmic localization. 
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A library of photoactive iridium complexes displaying cytoplasmic localization is 
shown in Fig. 1. The majority of complexes are cationic, and only a small number of neutral 
iridium(III) complexes have reported showing accumulation within the cytoplasm. As a 
general trend, the cytotoxicity of these probes is quite low. On comparing analogous neutral 
and cationic complexes, the neutral complexes show lower cytotoxicity than their 
corresponding cationic analogues, albeit in only one illustrated study.  
The first example of cyclometalated iridium(III) probes for the staining of the 
cytoplasm in living cells was reported by Li in 2008 [71]. Complexes 1 and 2 present the 
same fluorinated phenylpyridine moiety and different diamine ligands. The positive charge 
and the fluorination of the cyclometalated ligands, influencing the lipophilicity and aqueous 
solubility of the complexes, were argued to be the main factor for the internalization of 
these probes within the cells. Confocal images of live HeLa cells incubated with 1 and 2 in 
DMSO/PBS (1 : 49 v/v), at a concentration of 20 µM and for an incubation time of 10 
minutes, show intense intracellular luminescence with high signal-to-noise ratio between 
the cytoplasm (Ic) and the background (Ib), with a ratio of Ic/Ib over 50. Moreover, the effect 
of the two complexes on the proliferation of MCF-7 and HCT-8 cell lines was determined by 
MTS assay over a period of 24 h incubation, showing a cellular viability greater than 90% at 
the highest tested concentration (100 µM). 
Few years later, the same group expanded on the previously presented work by 
preparing the cationic iridium(III) complexes [63] 3, 4, and 5, whose structures are 
analogous to those of 1 and 2. The group also reported complex 6, where the two 
cyclometalating ligands are replaced by 2-phenylisoquinoline ligands and the diimine ligand 
is the neutral 2-(2-quinolyl)quinoxaline) [107]. The new complexes 3-6 show similar 
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biological properties in comparison to 1 and 2, albeit different photophysical behaviour, as it 
might be expected by the variation of the π conjugation within the various ligands. 
Significant emission color tuning from blue to deep red was obtained (λmax from 457 to 632 
nm) due to the modification of the ancillary diimine ligands (3-5), which was attributed to 
the corresponding energy variations of the 3MLCT [dπ(Ir)→ π*diimine] and 3LLCT [πCN → 
π*diimine] excited states. An increase in the conjugation of both cyclometalated and ancillary 
ligands further red-shifts the emission wavelength of 6 into the near-infrared region (λmax 
732 nm) [107]. Emission in the near-infrared region is particularly appealing to biological 
imaging as it facilitate signal discrimination from autofluorescence, reduces scattering, and 
allows for deeper penetration of biological samples [108,109]. Like the analogous complexes 
1 and 2, complexes 3-6 display predominant localization within the cytoplasm. Consistently 
within the small library of iridium(III) complexes, for cells incubated with complexes 3-6, the 
cellular viability after 24 h incubation time at a relatively high concentration (100 µM) was 
again ca. 90%.  
Complex 7 is the first example of neutral iridium(III) complex proposed for cellular 
imaging, which was reported by Zhao and Li. In this complex the two cyclometalating ligands 
are 2-phenylbenzothiazole and the remaining ligand is the bidentate anionic O-donor 
acetylacetate [72]. The complex was proposed as a radiometric luminescent sensor for the 
quantitation of cytoplasmic Hg(II) cations. In cuvette and upon addition of 1 equivalent of 
Hg(II), an acetonitrile solution of complex 7 shows a blue shift of ca. 40 nm of λmax that is 
evident in both the lowest energy absorption band and emission profile. The authors also 
illustrated how the shift is not affected by pH variations, within the range 2 - 12. When 
incubated within live HeLa and KB cells, complex 7 shows low cytotoxicity with values of 
viability ≥ 90% using 100 µM of 7 for 24 h. The applicability of 7 in the ratiometric 
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monitoring of intracellular Hg(II) was investigated by confocal microscopy using two optical 
windows: the green channel in the 515 ± 15 nm range, and the yellow channel in the 570 ± 
10 nm range. KB cells were incubated with 10 µM of the complex 7 and 10 µM of Hg(II) for 
timeframes of 15 mins, 1 h and 8 h. As it can be seen in Fig. 2, the ratio between the 
emission intensity at 515 and 570 nm (I515nm/I570nm) is negligible (ca. 0.1) when KB cells are 
stained with only complex 7.  Upon addition of Hg(II), I515nm/I570nm increased up to 0.6, 
confirming the ratiometric behaviour of complex 7.  
 
 
Fig. 2. Ratiometric phosphorescent images of 7 incubated in KB cells at a concentration of 
10 µM for 15 min. (A) KB cells stained with 7. (B) KB cells incubated with 7 and then treated 
with 100 µM of Hg(II) for 1 h. Reproduced with permission from ref [72]. 
 
The neutral diarylethene-based iridium(III) complex 8 was reported by Yi and Tian 
[73]. The complex was designed to improve the water solubility of a previously published 
analogue, by replacing the acetylacetonato ligand with deprotonated 2-picolinic acid [110]. 
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The MTT assay shows a cell viability greater than 80% with a concentration of 20 µM and 24 
h incubation time. By exploiting the reversible photoinduced ring opening and closing 
transformations of the diarylethene unit [111], the complex was proposed as a 
photoswitchable probe for live cells imaging triggered by visible light. Upon excitation at 488 
nm of a diluted tetrahydrofuran solution containing complex 8 with the ligands in their open 
form, a yellow/orange emission with λmax at 568 nm is detected. Upon continuous 
irradiation, the emission intensity of this band gradually decreases as the ligands undergo a 
photoinduced ring closing reaction, until no emission is detected. On the other hand, when 
the non-emissive closed form of complex 8 is continuously excited at wavelengths longer 
than 600 nm, the emission band with λmax at 568 nm intensity can be slowly recovered while 
the ligand reverses to its open form. Interestingly, a similar behaviour is detected from 
complex 8 when incubated within KB cells and irradiated with 458 nm of light for 2 minutes. 
The emissive open form is quenched and then recovered to the original state upon 
irradiation over 60 mins at 633 nm. Unfortunately, cellular damage is detected with these 
photoswitching experimental conditions, limiting the exploitation of the photoswitching 
properties of this probe in live cells.  
Zhao and Li reported the neutral β-diketonato iridium(III) complex 9, showing 
enhanced phosphorescent emission in the solid-state (EPESS) behaviour [74]. This complex 
exhibits very week luminescence (φ= 0.04%) in diluted solution, but the gradual addition of 
water causes an increase of the luminescent intensity that is ascribed by the authors to 
aggregation. Density functional theory (DFT) calculations illustrate the existence of π-π 
interactions involving the cyclometalated ligands, in support of the EPESS mechanism of 9. 
To explore the biological application of this EPESS-active complex, 9 was embedded in 
water-dispersible polymer nanoparticles with an average diameter of ca. 190 nm and 
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incubated in KB cells. These embedded 9-PNPs particles internalise in only 8 minutes within 
the cells and exclusively stain the cytoplasm. No cytotoxicity data were reported by the 
authors. 
Other neutral iridium(III) complexes (10a-c) were presented by Zhou [75], together 
with two charged biscarbene complexes (11a-b). In both neutral and cationic series, the 
introduction of the electron-withdrawing substituents -CN and -CF3 into the biscarbene 
ligand affects the emission maxima by inducing a hypsochromic shift in organic solvent, but 
an analogous clear trend was more difficult to elucidate from aqueous solutions. The 
authors showed that the lipophilicity value logPo/w is mainly influenced by the overall charge 
of the complex for this series, and the exchange of -CN for -CF3 is not greatly affecting the 
lipophilicity. The neutral complexes 10a-c exhibit higher logPo/w values (1.28 - 1.57) in 
comparison to 11a-b (0.56 - 0.89), a trend that is expected on passing from a neutral to a 
cationic complex. The MTT assay towards HeLa and A549 cell lines also proved the lower 
toxicity of neutral 10a-c versus charged 11a-b, with average IC50 values of ca. 165 µM and 
ca. 85 µM for the neutral and charged complexes, respectively. All the complexes display 
cytoplasmic localization and the authors determined that cellular internalization occurred 
through energy-dependent uptake. 
The iridium(III) complex 12 was proposed by Zhao, Li and Huang for hypoxia 
bioimaging [76]. Hypoxia is one of the most important feature of many diseases such as 
solid tumours, inflammatory diseases and cardiac ischemia [112–114]. Hence, monitoring of 
the oxygen level within cells is essential for the advancement of diagnostic and therapeutic 
techniques. The complex 12 was covalently attached to mesoporous silica-coated and 
lanthanide-doped core-shell nanoparticles (UCNPs@mSiO2). The use of a nanoparticle 
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carrier for the complex 12 was proposed in order to increase aqueous solubility and 
stability, as well as to facilitate the use of a continuous wave near-infrared (NIR) laser at 980 
nm with low excitation power density (ca. 102 W cm-2) [108]. The use of this excitation 
source was sought to minimize autofluorescence and cellular photodamage. The embedded 
nanoparticles 12-UCNPs@mSiO2 cannot be efficiently excited at 980 nm within cells. 
Nonetheless, upon conventional excitation at 405 nm, the probe shows responsiveness 
when incubated within cells with a gradient of O2. Additionally, the cytotoxicity was tested 
and the viability of HeLa cells result higher than 75% after 48 h at high concentration (600 
mg/mL). The authors showed that 12-UCNPs@mSiO2 stains the diffuse cytoplasm and cell 
membrane, with uptake occurring through a nonspecific endocytotic uptake. 
Three charged iridium(III)-based fluorogenic (turn-ON) bioorthogonal probes (13-15) 
were reported by Lo. All these complexes carry a nitrone functional group appended on the 
diimine ligand [77]. The nitrone unit can selectively and rapidly react with modified proteins 
which possess the specific alkyne reaction partner [115]. Furthermore, the incorporation of 
the nitrone group quenches the emission of the probe due to the photoisomerization of the 
C=N bond, which provides a non-radiative deactivation pathway [116,117]. After 
bioconjugation with the labelled proteins (bovine serum albumin BSA, human serum 
albumin HAS and holo-transferrin HTf), the complexes 13-15 show a remarkable 
enhancement of the emission intensity (I/I0 = 92.1 - 795.1). The intracellular distribution of 
the bioconjugated complexes 13-15 in CHO-K1 cell line highlights a cytoplasmic localization. 
Additionally, MTT assay showed that the probes are essentially non-cytotoxic toward the 
same cell line for an incubation period of 1 hour (IC50> 50 µM). 
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2.2 Nucleus & nucleolus staining 
The nucleus is a highly specialized organelle with two main functions: storing of the 
cellular hereditary material in form of DNA and coordination of many processes such as 
growth, intermediary metabolism, protein synthesis and cell division [118,119]. The nucleus 
is bonded by a double-membrane envelope that exhibits a two-way traffic to proteins and 
nucleic acid between nucleus and cytoplasm [120]. The most prominent membrane-less 
substructure within the nucleus is the nucleolus, which is the site of rRNA transcription and 
processing, and also of ribosome assembly [121,122].  
 
Fig. 3. Examples of iridium complexes with nuclear localization. 
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A library of iridium complexes that have been reported for the staining of the nucleus or the 
nucleolus is illustrated in Fig. 3. Of note, all the complexes described are cationic and there 
is no neutral iridium complex proposed as a nuclear stain.  
One of the first examples of nucleolar staining in live cells was proposed by Lan and 
Lo, with a series of iridium(III) dipydoquinoxaline complexes [78]. The modification in the 
chemical structure of the cyclometalated ligands (16a-18a) and the presence of a long chain 
on the dypidoquinoxaline (16b-18b) modulate the lipophilicity and cytotoxicity of the 
complexes. Extending the conjugation of the ligands increases the value of logPo/w 
(bzq>pq>ppy) [99,123] and the addition of an alkyl chain on the two phenyl rings of the 
cyclometalated ligand also results in an increment of the lipophilicity, especially in the case 
of a n-butyl substituent. The IC50 values of all the complexes towards HeLa and MDCK cell 
lines are lower than that of cisplatin, indicating high cytotoxicity, especially for the more 
lipophilic 17a-17b and 18a-18b. Localization studies with MDCK cell line revealed 
accumulation in the nucleus after 90 minutes of incubation, followed by a more specific 
nucleolar uptake after 120 minutes. In particular, it was proven that the complexes bind to 
the hydrophobic pockets of proteins and intercalate with DNA. 
The group of Li developed the non-emissive iridium(III) solvato complex 19, bound to 
two molecules of DMSO in place of a diimine ligand. This complex can react selectively with 
free histidine and histidine-rich proteins to increase its emission intensity of about 300-fold, 
in a fluorogenic turn-ON fashion [79]. The uptake in HeLa cell line of 19 (10 µM, 10 minutes 
incubation time) reveal an exclusive staining of the cell nuclei, with an energy-dependent 
internalization pathway. Moreover, the MTT assay toward HeLa, KB and FLS cell lines 
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showed low toxicity for complex 19, even after 48 hours, with values of viability greater 
than 90%.  
Based on the previous results, the same research group synthetized a series of non-
emissive iridium(III) complexes (20a-g) by varying the counter ions, the coordinated solvent 
and the substituent on the phenylpyridine ligands [80]. The structure-activity relationship 
studies showed how the nature of the counter ions and solvent ligands do not affect the 
behavior of the probes within cells. On the other hand, the length of the appended carbon 
chain significantly influences the cellular uptake and accumulation in living cells, showing 
nuclei staining for the shorter chain 20d and a diffused cytoplasmic accumulation for the 
longer 20f-g. 
Thomas and Smythe proposed two heterobimetallic iridium(III)-ruthenium(II) 
complexes 21-22 containing a tetrapyridophenazine as a bridging ligand [81]. The probes 
show good water-solubility, which is often the limiting factor of many cyclometalated 
systems [124]. Both complexes 21 and 22 display an unstructured red emission (ca. 640 nm) 
and low quantum yield (φ < 0.02%), which increases about 10 and 24-fold upon addition of 
DNA, respectively (Fig. 4). Interestingly, the binding affinity of 22 was lower than the non-
fluorinated analogue 21. The lower affinity was rationalized by the increased polarity of the 
probe, resulting in a decrease of affinity for DNA. However, the increased lipophilicity of 22 
enhances cellular uptake without loss of nuclear localization (Fig. 4). MTT assay 
demonstrated low cytotoxicity over a 24 hour incubation period for both 21 and 22 with IC50 
values of 56 and 43 µM, respectively.  
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Fig. 4. a) Co-staining of 21 (3) and 22 (4) with the nuclear stain DAPI in fixed HeLa cells; b) 
Isolated HeLa chromosomes stained with 21 (3). Reproduced with permission from ref [81]. 
 
The same authors reported complex 23 [82] as a more lipophilic analogue of the 
previously discussed complexes 21 and 22. The authors could therefore compare the 
behavior of these probes upon a systematic increase in lipophilicity, providing evidence that 
increasing the lipophilic character can be counterproductive for the uptake and the specific 
localization of the probe. In fact, the incubation of complex 23 in MCF-7 cells (10 µM, 24 
hour incubation time) results in poor intracellular emission and lack of nuclear staining. 
Subsequent binding tests proved that complex 23 interacts more strongly with bovine 
serum albumin, which inhibits the targeted nuclear accumulation.  
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2.3 Lysosomal staining 
Lysosomes are acidic organelles containing a variety of hydrolytic enzymes capable 
of degrading biomacromolecules delivered by ways of phagocytosis, autophagy and 
endocytosis [125,126]. Moreover, lysosomes participate in various other cellular processes 
as cell migration, intracellular transport, plasma membrane repair, apoptosis and exosome 
release [127–129]. Lysosomal dysfunctions are associated with diverse neurodegenerative 
and muscular diseases, lysosomal storage disease and cancer [130–132]. For these reasons, 
luminescent probes for the tracking of this organelles need to possess resistance to 
degradation, low toxicity, high photostability, great penetration depth, near-infrared or 
longer excitation wavelengths  and, more importantly, long-term localization [133,134].  
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Fig. 5. Examples of iridium complexes with lysosomial localization. 
 
Examples of iridium(III) complexes reported for the staining of lysosomes are shown 
in Fig. 5. While both neutral and cationic complexes have been proposed for lysosomial 
staining, the presence of protonable basic substituent seems to be a common factor for this 
family of complexes. This is not surprising given the lower pH of the lysosome environment. 
The group of Williams published the cyclometalated iridium(III) complex 24, carrying 
a 2-pyridyl-benzimidazole ligand, and its protonated analogue 25 [65]. Photophysical data in 
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dichloromethane solution shown a structured emission profile in the green region of the 
spectrum for 24, and an expected red shift for 25 with emission centered around 590 nm. 
Nevertheless, the emission profiles from CHO cells incubated with the probes at a 
concentration of 10 µM for 5 minutes are essentially identical. In fact, the protonation 
equilibrium between the two complexes is a function of the local pH, with 24 being the 
predominant form within the cellular environments regulated at pH values around 7.4. A 
shift is observed in acidic lysosomes, as the protonation equilibrium forms the red-shifted 
complex 25. The MTT assay evidenced low cytotoxicity of these probes, with IC50 values > 
200 µM (200 µM, 24 hours incubation) for both. 
A family of nine neutral iridium(III) complexes (26a-i) was synthesized by Velders. The 
complexes are functionalized with a different number (mono-, di-, tri-) and type (glycine, 
alanine, lysine) of amino acids on the 2-phenylpyridyl ligands [83]. The monosubstituted 
complexes 26a, 26d, and 26g show a remarkable 20-fold higher cellular uptake in 4T1 cells 
(10 µM, 1 hour incubation), a trend that was associated with the more lipophilic nature of 
the probes [135]. This result was supported by the authors with the determination of the 
theoretical lipophilicity (ClogP), which shows a distribution coefficient between 2.05 and 
3.18, in comparison to the negative values of ClogP for the di- (26b, 26e and 26h) and 
trisubstituted (26c, 26f and 26i) complexes. Analysis by flow cytometry showed a substantial 
reduction of the cell viability for the lysine-derivatives (26a-c), with higher toxicity for the 
more substituted complex 26c with viability lower than 39%. The cellular distribution of 
complexes 26a-c displays different localization, depending of the number of lysine residues, 
with nuclear staining for mono-26a, endosomes staining for bis-26b and lysosome staining 
for tris-26c.  
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Four iridium(III) complexes with β-carboline ligands (27-30) were developed by Tan 
and Mao as pH-responsive tumour/lysosome-targeted photodynamic therapeutic (PDT) 
agents [66]. The pH-response can be achieved with the introduction of the protonation sites 
on the imidazole and benzimidazole groups [136,137]. On the other hand, the selectivity 
toward acidic environment can be enhanced by the presence of the β-carboline ligand [138]. 
The complexes show similar lipophilicity values (1.97 - 2.12), with a greater cell penetration 
for the smaller imidazole-derivatives 27-28. Upon irradiation, they show highly selective 
phototoxicity against A549 cancer cells. In particular, complex 28 displays a phototoxicity 
index of greater than 833. Even if all the complexes localize within the lysosome, 28 is the 
more promising to be used to track the lysosomal integrity during PDT, which provides a 
convenient method for in situ monitoring of therapeutic effects.  
The group of Aoki developed a neutral iridium(III) probe 31 that can be used as 
luminescent pH-sensor and also a pH-dependent photosensitizer in live cells [84]. 
Photophysical analysis in degassed DMSO/100 µM aqueous buffer have shown a blue 
shifted emission maximum upon addition of 1 equivalent of acid, and an enhancement of 
the emission intensity induced by the second and third protonation of the diethylamino 
groups. As predicted, through a passive transport mechanism, complex 31 localizes within 
the lysosomes of HeLa-S3 cells. Additionally, photoirradiation of 31 at 377 and 470 nm for 
30 minutes induces necrosis-like death in HeLa-S3 cells, demonstrating the ability of the 
probe to generate 1O2 in a pH-dependant manner. 
An interesting neutral iridium(III) probe for a long-term lysosomes tracking was 
designed by Chao [85]. The water-soluble triscyclometalated iridum(III) complex is 
functionalized by morpholine moieties, which can be protonated inside the lysosome [139] 
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and work as a “locker”, allowing the accumulation of 32 in these acidic organelles (Fig. 6). 
Additionally, the electron-rich morpholine quenches the iridium(III) phosphorescence by 
photoinduced electron transfer (PET) in basic condition, but upon protonation this process is 
suppressed, leading to an enhancement of the emission intensity in acidic lysosomes. The 
uptake of complex 32 occurs through an energy-dependent pathway and the probe results 
nontoxic for HeLa cell lines (10 µM, 48 hour incubation). Moreover, 32 is able to track 
lysosomes for a period of 4 days, allowing imaging and observation of most physiological 
activities of the lysosomes. 
 
Fig. 6. Normalized emission intensities and images of living HeLa cells stained with 2 µM of 
complex 32 (Ir-lyso) and 2 µM of LysoTracker Red DND-99 (LTR) at different passages. Scale 
bar: 100 µm. Reproduced with permission from ref [85]. 
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2.4 Mitochondrial staining 
Mitochondria are rod-shaped organelles performing diverse functions, involving 
energy production via oxidative phosphorylation, calcium modulation, redox signalling, and 
apoptosis [140,141]. Furthermore, mitochondria are dynamic organelles that frequently 
change their number, size, shape and distribution within the cytoplasm in response to 
metabolic and environmental stress [142]. It is therefore not surprising that mitochondrial 
dysfunction has emerged as a key factor in a range of diseases, including metabolic 
disorders, cancer and neurodegenerative diseases, such as Alzheimer and Parkinson [143].  
Fig. 7 illustrates various iridium(III) complexes reported to localize within the 
mitochondria. The majority of the complexes are positively charged, with very limited 
examples of neutral species developed for the staining of mitochondria. In general, the 
requirement of a positive charge is associated to a facilitation of mitochondrial localization 
through the membrane electrical potential.  
A charged iridium(III) complex carrying a phenanthroline ligand and functionalized 
with a isothiocyanate group (33) was developed to target specific mitochondrial proteins 
[86]. As a previous study showed [100], the isothiocyanate unit allows the probe to 
covalently bind to amine-containing biomolecules such as lysine and the N-terminal of 
proteins, yielding luminescent bioconjugates. Interestingly, complex 33 accumulates only in 
the mitochondria of living 3T3, HeLa and RPE cells, while a diffuse staining is present with 
prefixed 3T3 cells, indicating that the process requires active cellular metabolism. The 
binding of complex 33 to mitochondrial proteins interferes with the function and the 
morphology of this organelle, as showed in the MTT assay. The viability of 3T3 cells 
decreases to 60% with concentration higher than 10 µM and an incubation time of 12 hours. 
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Another series of bioconjugated iridium(III) complexes was proposed by Lo [87]. In 
this case, the complexes are appended with a β-D-glucose (34a-d) or a D-galactose unit 
(35a-d) via a polyethylene glycol linker to the diimine ligand, while the degree of π 
conjugation was varied on the cyclometalated ligands. The general idea is to increase the 
specific cellular uptake of these sugar-appended probes in cancer cells, which usually show 
an elevated expression of glucose transporters (GLUTs) and hexokinase to support their 
higher metabolic functions [144,145]. The lipophilicity was tested highlighting the main 
contributing factor was the nature of the cyclometaled ligands(a, c, d>>b). In fact, the 
complexes of the groups 34 and 35 show similar values of lipophilicity when the 
cyclometalated ligand is the same. Overall, the lipophilicities of 34(a-d) and 35(a-d) are 
slightly lower than 36, illustrating the effect of the polar carbohydrate groups. Additionally, 
the cytotoxicity toward HeLa cells (50 µM, 48 hours) displays lower IC50 values in 
comparison to cisplatin for almost all the probes. Both 34a and 35a localize within 
mitochondria through an energy-dependent pathway, but only complex 34a enters the cells 
using a GLUT-mediated mechanism. 
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Fig. 7. Examples of iridium(III) complexes displaying localization within the mitochondria. 
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Two charged bioorthogonal iridium(III) probes (37-38) were reported by Lo. The 
complexes are appended with a dibenzocyclooctyne moiety [88], which is capable of 
targeting different azide-labelled biomolecules [146]. Lipophilicity studies of 37 and 38 
revealed very high values of 5.69 and 7.14, respectively. Both complexes exhibit 
mitochondrial localization in CHO cells achieved through a passive diffusion. Regardless of 
the higher lipophilicity of 38, complex 37 enters the cells more efficiently, suggesting that 
the smaller molecular size plays a critical role in the uptake of the probe. Both complexes 
exhibit a moderate cytotoxicity with a percentage of surviving CHO cell of 75.6% and 84.9%, 
at a concentration of 50 µM for an incubation time of 6 hours. 
After their previous publication on pH-responsive probes [84], the group of Aoki 
synthesized a further neutral iridium(III) analogue containing three pyridyl groups at the 4’-
position of the phenylpyridine ligand (39) [89]. Complex 39 exhibits a reversible pH-
dependent emission profile based on protonation and deprotonation on the pyridine rings, 
with a green intense emission in neutral and basic condition and a weaker red emission in 
acidic pH. Upon incubation in HeLa-S3 cells, complex 39 accumulates within mitochondria, 
potentially through a passive transport mechanism. Moreover, after photoirradiation at 465 
nm for 10 minutes, 39 generates much more 1O2 in comparison to the previous published 
iridium(III) probe [84], thus inducing necrosis-like cell death. 
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Fig. 8. Confocal images of adherent A549 cells treated with 5 µM of complexes 40-43 (Ir1-
Ir4) under normoxic (20% O2) and different hypoxic (15, 10, 5 and 1% O2) conditions. Scale 
bar: 10 µm. Reproduced with permission from ref [90]. 
 
The group of Chao developed four iridium(III) anthraquinone complexes (40-43) that 
can be excited via two-photon absorption, as hypoxia-sensitive imaging probes [90]. The 
anthraquinone unit is an efficient quencher of the iridium luminescence. However, in 
hypoxic conditions, it can be converted into the hydroquinone form, thus restoring the 
emission of the probe [147]. In cells, the ligand can be reduced by the coenzyme 
nicotinamide adenine reductase phosphate (NAD(P)H) in the presence of cellular reductase 
[148]. Interestingly as shown in Fig. 8, the emission intensity of the complexes 40-43 
internalized within A549 cells rapidly increases (11- to 19-fold) after enzymatic reactions 
with NAD(P)H in hypoxic condition, without interference from other biological reductants. 
Moreover, the probes display different sensitivity toward oxygen, with an increment of 
phosphorescence at [O2] ≤5% for 40, and 1% or less for 41-43. All the probes localize in the 
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mitochondria of A549 cells and show quite low cytotoxicity with viability values greather 
than 80% under both normoxic and hypoxic conditions, after 12 hours incubation at a 
concentration of 10 µM. 
A series of photoactivatable iridium(III) (44a-c) complexes functionalized with a 
nitroveratryl photolabile protecting group and polyethylene glycol chains of various lengths 
were designed by Lo [91]. The polyethylene glycol chain increases water solubility [149], and 
also reduces the toxicity as the chain increases in length. In fact, despite similar uptake 
efficiency within this small family of complexes, the viability in the dark of HeLa cells 
incubated with 44a and 44b (>80%) is higher than for 44c (>60%), due to the greater 
biocompatibility of the longer polyethylene glycol chain. Upon irradiation for 5 minutes, the 
nitroveratryl group is cleaved and the cytotoxic iridium(III) core is released, showing a 
significant decrease of the percentage of cell survival. The complexes 44a-b display good 
accumulation within the mitochondria. 
The group of Chao synthesized five iridium(III) complexes (45a-e) [64] with 
aggregation-induced emission (AIE) characteristics, showing almost no fluorescence in 
solution and high emission in the aggregated state [150]. All the complexes exhibit low 
toxicity (viability >85%), upon incubation at 500 nM for a period of 12 hours. The uptake in 
the mitochondria of HeLa cells follows a non-endocytic energy dependent process. 
Remarkably, 45a was employed to successfully monitor a mitophagy [151] process in living 
cells. 
 The same research group recently published a similar series of AIE-active iridium(III) 
probes (46-48), which are analogous to the family of complexes 45 with variations in the 
cyclometalated ligands. In line with the previously reported complexes, these species can 
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also be used as a two-photon absorbing agents for photodynamic therapy (PDT) [92]. In 
particular, the complex 46 displays a significant two-photon absorption cross-section, a 
really high ROS (reactive oxygen species) generation capacity and an impressive lethality at 
low concentration upon aggregation within mitochondria. 
Another family of terpyridyl iridium(III) complexes (49a-c) for the real-time dynamic 
tracking of mitophagy [151] with two-photon excitation was proposed by Chao [93]. These 
probes exhibit lipophilicity values logD7.4 in a range between 0.9 and 1.5 and moderate 
cytotoxicity in HeLa cells, with a viability greater than 80% after 6 hour incubation at a 
concentration of 5 µM. Interestingly, the complexes 49a-c are capable of localizing within 
the mitochondria independently of the membrane potential, an advantageous characteristic 
over the commercially available mitochondrial stain MitoTracker Red (which in the absence 
of membrane potential distributes within the cytoplasm and other organelles). Moreover, 
49a-c show deep tissue penetration under two-photon excitation, enabling the visualisation 
of the inner structure of tridimensional multicellular tumour spheroids [152]. 
Laskar and Chowdhury designed two of the few examples of neutral iridium(III) 
probes (50-51) for the staining of mitochondria [94]. As Chao’s probes [64,92], 50 and 51 
exhibit aggregation induced emission with an increment of the emission intensity in the 
solid state 60 and 34 times higher than in solution, respectively. Additionally, these 
complexes show a low toxicity at concentration lower than 5 µM (viability >80%) for an 
incubation time of 24 hours in HOS cells and specific mitochondrial staining. 
Mao and Tan synthesized two chloromethyl functionalized iridium(III) complexes 
(52-53) with differently functionalized bipyridine as diimine ligands [95]. These complexes 
are designed to react with thiol functional groups present in various mitochondrial proteins 
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and immobilize the complexes inside this organelle [153]. The cytotoxicity of 52-53 was 
tested against a series of cancer cell lines, showing very low IC50 values (0.2 - 27 µM) after 
48 hour treatment. Additionally, 52 shows a 11-fold higher selectivity for cancerous A459 
cells over noncancerous LO2 cells, inducing a caspase-dependent and ROS-mediated 
apoptotic cell death [154]. 
 
Fig. 9. Phosphorescent images of CCCP (carbonyl cyanide m-chlorophenyl hydrazone) (10 
µM) treated living HeLa cells stained with 20 µM of 55(Ir2) and an increasing scan time. The 
upper panels are the luminescence images of Ir2 (55), the middle panels are the bright-field 
(BF) images, whereas the lower panels are the merged images. Reproduced with permission 
from ref [96]. 
 
The complexes 54 and 55 are some of the few examples of NIR iridium(III) probes 
[96], due to the presence of phenylbenzo[g]quinoline as cyclometalated ligands [109]. These 
complexes display a strong emission band around ca. 750 nm, superior photostability and 
reduced pH dependence of the phosphorescent intensity. Those properties, in addition to a 
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low cytotoxicity with viability greater than 70% after 24 hour of incubation at 20 µM in HeLa 
cells, have allowed to track the changing in the mitochondrial morphology during the early 
stage of apoptosis (Fig. 9). 
Based on the structure of previously reported iridium(III) derivatives [64,155], the 
group of Chao synthesized a family of complexes to assess the effect of various degrees of 
fluorination on anti-proliferation [97]. In particular, the complex with the highest degree of 
fluorination (56) shows high cytotoxicity against 5 different human cancer cell lines (IC50 
values: 0.5 - 2.6 µM) with also the highest selectivity to the cisplatin-resistant cell line 
A549R.  
Our research group developed two charged iridium(III) tetrazolato complexes, 
functionalized with a cyano unit (57-58) [98]. Both complexes localize within the 
mitochondria in live cardiomyoblast H9c2 cells. Interestingly, complex 57 is also found 
within the endoplasmic reticulum, whereas complex 58 almost exclusively accumulate 
within the mitochondria. These two complexes display similar value of lipophilicity (1.86 and 
1.87 for 57 and 58, respectively) and similar incubation within cells as revealed by ICP-MS 
[98]. These complexes are characterized by high cytotoxicity when incubated at 20 μM for 
24 hours.  
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2.5 Endoplasmic reticulum staining 
The endoplasmic reticulum (ER) is the largest membrane-bound organelle in 
eukaryotic cells and it consists of multiple structural domain that are interconnected and 
contiguous [156]. The ER serves different roles within the cell such as protein folding, lipid 
and steroid synthesis, carbohydrate metabolism and calcium storage and release [157]. 
Importantly, a number of physiological and pathological conditions are known to disturb 
proper ER function and thereby cause ER stress, which can lead to unfolded protein 
response (UPR) or the release of calcium in the cytoplasm, followed by mitochondria 
mediated apoptosis [158,159].  
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Fig. 10. Iridium complexes proposed for the staining of the endoplasmic reticulum. 
 
A family of iridium(III) complexes that display localization within the endoplasmic 
reticulum is shown in Fig. 10. A look over these complexes highlights that the majority of 
them are cationic and exhibit acute cytotoxicity. On the other hand, neutral complexes with 
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accumulation within the endoplasmic reticulum appear to exhibit lower cytotoxicity, even at 
longer incubation time.  
One of the first examples of ER probes was a series of charged iridium(III) complexes 
appended with an indole moiety (59a-c/60a-c) [99]. In fact, the binding properties of the 
indole unit with proteins such as serum albumin, which contains six specific substrate-
binding sites [160,161] are well known. Lipophilicity measurements shown slightly higher 
values for the probes with a longer spacer (60a-c), compared with their analogues (59a-c), 
and increased logD7.4 along with the higher conjugation of the two cyclometalating ligands 
(c>b>a). Additionally, all the probes display high levels of cytotoxicity toward HeLa cell, with 
IC50 values ranged from 1.1 to 6.3 µM at 48 hour incubation time. Through an energy-
requiring process such as endocytosis, 60a localized in the perinuclear area of cells. 
A family of three iridium(III) complexes bound to functionalized 1,10-phenanthroline 
ligands (61-63) was studied by the group of Lo [100]. The complex 63 was the only probe in 
the series that can undergo bioconjugation with proteins, such as bovine serum albumin or 
human serum albumin. Surprisingly, the intracellular distribution of 61-63 in HeLa cells was 
the same, with the formation of a luminescent ring surrounding the nucleus. Additionally, 
cytotoxicity data have shown similar IC50 values (1.0 – 4.2 µM), revealing the high toxicity of 
these probes. 
The bathophenanthroline iridium(III) probe 64 was discovered by Fei and Zhou [162]. 
The size and the conjugation degree of the diimine ligand increases the lipophilicity and 
cytotoxicity of complex 63 in comparison with a previous published analogue [163]. The 
greater lipophilicity causes the localization of the probes in the membrane of the 
endoplasmic reticulum, causing ER stress and initiating an intrinsic apoptotic pathway 
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[158,159]. Additionally, the high cytotoxicity against HeLa, A549 and MCF-7 cell lines has 
highlighted the antitumor potential of 64, with IC50 values of 3.3, 2.0 and 3.2 µM, 
respectively. 
The bioorthogonal iridium(III) complex 65 containing a 1,2,4,5-tetrazine moiety is almost 
non-emissive, but its emission highly enhances upon selective coordination with modified 
bovine serum albumin (I/I0= 1113.7) [102]. The cytotoxicity of the probe was tested by MTT 
assay on CHO-K1 cells and shows a viability greater than 80% after 20 hour incubation at 
concentration up to 20 µM. The localization of complex 65 shows a perinuclear and sharp 
granular cytoplasmic staining, due to the dynamic recycling of the probe from the 
endoplasmic reticulum to subcellular organelles for enzymatic processing [164]. 
Kwon, Rhee and Lim reported two bipyridine iridium(III) complexes (66-67) which 
can be used as PDT (photodynamic therapy) agents, due to their high efficiency in the 
production of ROS [103]. In fact, at really low concentration (2 µM) the probes can be 
photoactivated (10 second irradiation time, 100 J cm-2 light) and reduce significantly the cell 
viability of SKOV-3 cancer cells, with IC50 values of 4.89/0.83 µM (66) and 3.61/0.63 µM (67) 
in the absence/presence of light. Interestingly, the localization of the probes was mainly in 
the endoplasmic reticulum, but the 1O2 produced might be diffused through the ER 
membrane and also modify some mitochondrial proteins, by protein-protein cross-linking 
and protein oxidation mechanisms. 
Our research group developed a series of neutral iridium(III) tetrazolato probes (68a-
b, 69, 70, 71a), which predominantly stain ER of H9c2 cells (Fig. 11) [98]. Noteworthy, the 
MTS assay has showed low cytotoxicity at 40 µM and 24 h incubation time, with a cell 
viability greater than 85%, and an active transport mechanism for the internalization of 
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these probes. Interestingly, the probes localized also within lipid droplets, as seen for the 
complexes 70 and 71a in Fig. 11, to various degrees, which is not very commonly observed 
for cyclometalated iridium(III) complexes [165,166]. The charged 71b exhibits the same 
stain pattern than the neutral compounds, but it shows high toxicity toward H9c2 cells. 
 
Fig. 11. Iridium complexes (from the top 68-71b) interacting with endoplasmic reticulum in 
live H9c2 cells. Micrographs of H9c2 cells stained with the iridium complexes (green) and ER 
Tracker (red). Scale bar: 10 µm. Reproduced with permission from ref [98]. 
 
3. Outlook and conclusions 
This review surveyed the research area of cyclometalated iridium(III) complexes and 
their use in life science. It is evident that this area is still incredibly active and it has been 
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diversified over the years. While phosphorescent iridium(III) complexes were initially 
screened as cellular markers for optical imaging, their versatility has expended potential use 
in broader areas including therapy. Despite the large body of work that has appeared in the 
literature to date, a full rationalization of structure-activity relationship is still difficult to 
achieve. Most of the design of new iridium probes and/or therapeutic agents starts with 
considerations of chemical nature such as charge, lipophilicity, solubility and bioconjugation 
to specific biological vectors. However, as illustrated in the various examples within this 
review, a systematic investigation related to a biological context is lacking. In fact, the 
various research groups have been tested the iridium complexes in very different conditions 
including diverse cell lines, concentration and incubation time. The area, in its 
multidisciplinary feature bridging chemistry and biology, would certainly benefit for the 
establishment of a set of conditions to assess newly synthesized iridium(III) complexes and 
to revise currently available ones. Nevertheless, it is very evident that the future research 
involving the use of cyclometalated iridium complexes in life science is certainly active and 
bright. 
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